Scholarlink

Histone deacetylase inhibitors (HDACIs) have emerged as promising therapeutic candidates for neurodegenerative disorders due to their neuroprotective and cognitive-enhancing effects. This chapter examines the potential of HDACIs in Alzheimer’s, Parkinson’s, Huntington’s disease, and amyotrophic lateral sclerosis. Dysregulated HDAC-mediated epigenetic control plays a critical role in disease pathogenesis. HDACIs exert multifaceted actions, including epigenetic modulation, anti-inflammatory, neurotrophic, and antioxidant effects. Preclinical studies demonstrate reduced protein aggregation, attenuated neuroinflammation, and improved synaptic plasticity. Recent advances emphasize isoform-selective HDACIs to minimize offtarget effects. Key challenges include blood–brain barrier penetration, isoform specificity, and dose optimization. Targeted HDACI strategies may help address the multifactorial nature of neurodegenerative diseases.

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Therapeutic Potential of HDAC Inhibitors in Neurodegenerative Diseases

  • 章节

  • 发表日期：

    2026年

查看全文
  • Abhay Kumar Singh,
  • Yemgadda Goutham Sudhan,
  • Sudharshanam Lakshmi Chandana,
  • Ashok Iyaswamy,
  • Siva Sundara Kumar Durairajan

摘要

Histone deacetylase inhibitors (HDACIs) have emerged as promising therapeutic candidates for neurodegenerative disorders due to their neuroprotective and cognitive-enhancing effects. This chapter examines the potential of HDACIs in Alzheimer’s, Parkinson’s, Huntington’s disease, and amyotrophic lateral sclerosis. Dysregulated HDAC-mediated epigenetic control plays a critical role in disease pathogenesis. HDACIs exert multifaceted actions, including epigenetic modulation, anti-inflammatory, neurotrophic, and antioxidant effects. Preclinical studies demonstrate reduced protein aggregation, attenuated neuroinflammation, and improved synaptic plasticity. Recent advances emphasize isoform-selective HDACIs to minimize offtarget effects. Key challenges include blood–brain barrier penetration, isoform specificity, and dose optimization. Targeted HDACI strategies may help address the multifactorial nature of neurodegenerative diseases.